Rigopoulos, A. G.
Bakogiannis, C.
de Vecchis, R.
Sakellaropoulos, S.
Ali, M.
Teren, M.
Matiakis, M.
Tschoepe, C.
Noutsias, M. http://orcid.org/0000-0002-9066-5262
Article History
Received: 1 September 2017
Revised: 1 September 2017
Accepted: 1 September 2017
First Online: 22 September 2017
Compliance with ethical guidelines
:
: A.G. Rigopoulos, R. de Vecchis, S. Sakellaropoulos, M. Ali, M. Teren and M. Matiakis declare that they have no competing interests. C. Bakogiannis was employed by Novartis from August 2013 to July 2015. M. Noutsias received grants from the Deutsche Forschungsgemeinschaft (DFG) through the Sonderforschungsbereich Transregio 19 “Inflammatory Cardiomyopathy” (SFB TR19) (TP B2) and from the University Hospital Gießen and Marburg Foundation Grant “T cell functionality” (UKGM 10/2009). He was consultant to the Institute for Cardiac Diagnosis and Therapy (IKDT, Berlin) from June 2004 to June 2008, and received fees for presentations and/or participation in advisory boards from AstraZeneca, Bayer, Fresenius, Miltenyi Biotech, Novartis, Pfizer and Zoll and is the local principal investigator (p. i.) of the trials RELAX-AHF-2, TRUE-HF and TRANSITION trials at the University Hospital Jena. C. Tschoepe received a grant by the DFG (SFB TR19 TP B5 and Z3).
: This article does not contain any studies with human participants or animals performed by any of the authors.